Physician profile
Jonathan Kushner
NPI 1235146390
$1,384.98
in general payments reported to CMS, 2019-2025
25 companies · $288 in 2025
The $288 reported for 2025 was more than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $645 · 2020: $129 · 2023: $76.53 · 2024: $247 · 2025: $288.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $611.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $611.11 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $251.11 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Abbvie INC. | $176.26 | 2023-2025 | |
| Astrazeneca Pharmaceuticals LP | $142.10 | 2019-2025 | Airsupra, Breztri |
| Lilly USA, LLC | $85.30 | 2019-2024 | Mounjaro, Zepbound |
| Novartis Pharmaceuticals Corporation | $84.54 | 2019-2023 | |
| Sanofi-Aventis U.S. LLC | $67.32 | 2019-2020 | |
| Amgen INC. | $59.96 | 2019-2025 | Krystexxa |
| Janssen Pharmaceuticals, INC | $59.53 | 2019-2020 | |
| Exact Sciences Corporation | $43.62 | 2024-2025 | Cologuard Collection Kit |
| Glaxosmithkline, LLC. | $40.64 | 2019-2024 | Trelegy Ellipta |
| Teva Pharmaceuticals USA, INC. | $40.14 | 2019 | |
| Amarin Pharma, INC. | $39.84 | 2019 | |
| Radius Health, INC. | $34.46 | 2019 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $28.73 | 2020 | |
| Aerin Medical INC. | $25.36 | 2025 |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $24.39 | 2019 | |
| Daiichi Sankyo INC. | $24.16 | 2019 | |
| Allergan, INC. | $23.53 | 2020 | |
| Ucb, INC. | $23.17 | 2024 | Nayzilam |
| Merck Sharp & Dohme LLC | $21.98 | 2019 | |
| Pfizer INC. | $20.04 | 2024 | |
| Valeritas, INC. | $18.48 | 2019 | |
| Astellas Pharma US INC | $18.32 | 2024 | Veozah |
| Bayer Healthcare Pharmaceuticals INC. | $17.85 | 2025 | |
| Abbott Laboratories | $14.15 | 2023 | Freestyle Libre 3 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jonathan Kushner listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.